Tamtam Try Tamtam free
hims & hers logo

hims & hers account plan

Telehealth healthcare platform

At a glance

Hims & Hers Health (NYSE: HIMS) runs a consumer telehealth platform with FY2025 revenue of $2,347.6 million and 2,442 employees.

Hims & Hers Health, Inc. (NYSE: HIMS) launched in 2017 and runs a consumer-first telehealth platform covering sexual health, hair loss, hormone health, weight loss, dermatology and mental health, plus laboratory testing. Customers buy through websites and mobile apps and are connected to licensed providers, with prescriptions fulfilled by licensed pharmacies, many of them company-owned. It operates in the United States, the United Kingdom, parts of the European Union and Canada, and added Australia and Japan with Eucalyptus in June 2026. FY2025 revenue was $2,347.6 million, up 59%, with net income of $128.4 million and 2,442 employees at December 31, 2025. The company is independent and listed, and Andrew Dudum is Co-Founder, Chairman and CEO.

Business units

Strategic priorities

Win metabolic health
Management's first commitment is to win metabolic health in the U.S. and around the world, through a Novo Nordisk collaboration and a Lilly agreement for Zepbound and Foundayo, with multi-month subscriptions planned. Since March 2026 the US weight loss offering centres on branded GLP-1 medications, with compounded GLP-1s offered on a limited scale.
Lead in major international markets
The company directs more investment to the U.K., Germany and Australia and is consolidating brands under Hims & Hers. International revenue is expected to be at least $650 million in 2026, and the CEO says it is on track to eclipse a $1 billion revenue run rate in 2027.
AI-native care platform
The AI-native experience reached 70% of weight loss subscribers at the end of Q3 2026, with nearly 100% expected before year-end. Customers using it send 4x as many messages, and the company says it is aimed at engagement, retention and lower cost to serve.
Category expansion
Injectable and oral testosterone launched as the first controlled substances, and a peptides offering (Sermorelin, Glutathione, NAD+) is planned for later in November 2026. BPC-157 and TB-500 depend on regulatory clarity. The 10-K names sleep disorders, post-traumatic stress disorder, fertility, diabetes, cholesterol and hypertension as future specialties.
Internal fulfillment
The company wants a significant majority of pharmaceutical and over-the-counter orders fulfilled internally, through two 503A pharmacies, a 503B outsourcing facility, a peptide facility and a lab facility. Facility expansion is expected to continue for at least the next 12 months.
2030 ambitions
On the Q2 2026 call the CFO reiterated 2030 ambitions of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.

Latest results

In the quarter ended September 30, 2026, revenue was $890.4 million, up 49% from $599.0 million, with a net loss of $33.0 million and Adjusted EBITDA of $82,388 thousand (9% margin). Gross margin fell to 57% from 74%, mainly from weight loss offerings with shorter shipping cadences, international growth and acquisitions. Subscribers were 2,788 thousand, up 13% year on year but down 100,000 sequentially after deliberately measured domestic weight loss marketing. Guidance for Q4 2026 is revenue of $875 million to $895 million; for 2026, revenue of $3.13 billion to $3.15 billion and adjusted EBITDA of $257 million to $277 million (reduced). Liquidity was $712.2 million at September 30, 2026.

Investments and deals

Eucalyptus acquisition
Closed in June 2026 for a purchase price for accounting purposes of $968.5 million, including $225.0 million upfront and $683.9 million of deferred payments in six quarterly installments.
YourBio Health merger
Completed in January 2026 to bring in capillary whole blood sampling technology, with a purchase price for accounting purposes of $153.0 million.
Zava and Medici
Zava was acquired in July 2025 (EUR 219.2 million, or $258.0 million) and Medici in Canada in November 2025 (CAD 39.1 million, or $27.8 million).
Financing
$1.0 billion of 0% convertible senior notes due 2030 (May 2025), $402.5 million due 2032 (May 2026), and a receivables purchase agreement with a $400.0 million uncommitted limit (July 2026).
Technology and AI hiring
The CTO and CFO described Q3 2026 as the largest hiring quarter in the history of the engineering organization, and an AI R&D lab in Menlo Park was planned on the Q2 2026 call.

Challenges and risks

Compounded GLP-1 regulation
The FDA resolved the semaglutide shortage on February 21, 2025, and in February 2026 stated it intends to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, naming the company. HHS said it referred the company to the DOJ for investigation, and the 10-K says it is unclear what actions may follow.
Litigation
Novo Nordisk filed a patent infringement lawsuit on February 9, 2026, and a securities class action is pending. On July 29, 2026 the FTC and others filed a complaint over subscription and cancellation practices, for which the company accrued approximately $60 million and has filed a motion to dismiss.
Margin pressure
Gross margin was 57% in the third quarter of 2026 against 74%, from branded weight loss, shorter shipping cadences and international mix; management expects the decline to start to moderate.
Subscriber volatility
Subscribers declined by 100,000 sequentially in Q3 2026, and the company warns of another quarter of headwinds from moderated US weight loss marketing and international brand consolidation.
Dependence on affiliated medical groups
US clinical services are provided by Affiliated Medical Groups the company does not own, and the 10-K flags the risk that a regulator asserts corporate practice of medicine or fee-splitting violations.

What leadership says

“Our conviction is simple in healthcare, whoever owns the customer relationship wins.”

Andrew Dudum, Co-Founder, Chairman and CEO · Third Quarter 2026 Earnings Call, November 9, 2026

“the choice trades near-term subscriber growth for what we believe is a stronger long-term position.”

Yemi Okupe, Chief Financial Officer · Third Quarter 2026 Earnings Call, November 9, 2026

“We are making AI load-bearing, not decorative.”

Mohamed ElShenawy, Chief Technology Officer · Second Quarter 2026 Earnings Call, August 10, 2026

Where a supplier can help

AI-native care and support tooling
The AI-native experience (70% of weight loss subscribers) and the stated aim to reduce reliance on agentic AI customer support vendors point to demand for clinical AI, evaluation and audit tooling, but also to a build-over-buy stance.
Fulfillment and compounding infrastructure
The internal fulfillment priority and continued facility expansion over the next 12 months create needs for pharmacy automation, quality, cold-chain and laboratory supplier relationships.
International expansion services
With brand consolidation in the U.K., Germany and Australia and at least $650 million of expected 2026 international revenue, local compliance, payments, localisation and marketing partners could be relevant.
Regulatory and legal support
The FDA statement, the HHS referral, the Novo Nordisk and FTC matters make regulatory counsel, compliance monitoring and subscription-practice audit capabilities relevant.
Cost-of-capital and working capital tools
The receivables purchase agreement, convertible notes and a working capital deficit of $114.8 million suggest interest in receivables financing and treasury solutions.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like hims & hers?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about hims & hers

What does Hims & Hers Health do?

It runs a consumer-first telehealth platform that connects customers to licensed providers for conditions such as sexual health, hair loss, hormone health, weight loss, dermatology and mental health, with prescriptions fulfilled by licensed pharmacies. It also sells non-prescription health and wellness products.

How large is Hims & Hers Health?

FY2025 revenue was $2,347.6 million, up 59%, with net income of $128.4 million. It had 2,442 employees and approximately 2,511,000 Subscribers at December 31, 2025.

What is Hims & Hers Health's strategy?

Management's three commitments are to win metabolic health, lead the major markets globally and lead category expansion, supported by an AI-native platform and internal pharmacy and lab infrastructure.

Who leads Hims & Hers Health?

Andrew Dudum is Co-Founder, Chairman and CEO. Yemi Okupe is Chief Financial Officer and Mohamed ElShenawy is Chief Technology Officer.

What is the regulatory position on compounded GLP-1s?

The company's filings state that the FDA, in February 2026, said it intends to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs and named the company, and that HHS referred it to the DOJ. Since March 2026 its US weight loss offering centres on branded GLP-1 medications.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)